Myeloproliferative neoplasms
Targeted therapies for myeloproliferative neoplasms
... BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment ...
8
TET2 Mutations in Ph Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings
... in 12% - 24% of acute myeloid leukemia (AML), in 20% - 40% of chronic myelomonocytic leukemia (CMML), and in 29% of systemic mastocytosis [2-9]. Moreover, at the best of our knowledge, no significant correlation was ...
6
The Prevalence of JAK2 -V617F Mutation in Sudanese Patients with Chronic Myeloproliferative Neoplasms
... Myeloproliferative neoplasms (MPNs) are clonal malignant diseases that represent a group of conditions including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis ...with ...
7
HSP90 is a therapeutic target in JAK2 dependent myeloproliferative neoplasms in mice and humans
... Myeloproliferative neoplasms (MPNs) comprise a group of clonal hematological malignancies that include chronic myeloid leuke- mia (CML), polycythemia vera (PV), essential thrombocytosis (ET), and primary ...
17
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
... Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the ...
6
The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study
... Patients with IBD frequently have hematologic abnormalities suggestive of JAK2 mutated MPNs, but are traditionally classified as reactive processes. Haplotype 46/1 is a well-characterized genetic predisposition, common ...
6
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
... Abstract: An important pathogenetic distinction in the classification of myeloproliferative neoplasms (MPNs) is the presence or absence of the BCR–ABL fusion gene, which encodes a unique oncogenic tyrosine ...
21
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.
... the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), and chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and acute myeloid ...
9
Myeloproliferative neoplasms (MPNs) – Part 1: An overview of the diagnosis and treatment of the “classical” MPNs
... Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone mar- row stem cells. The symptom burden experienced by patients with the ...
8
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
... Myeloproliferative neoplasms (MPNs) are chronic hema- topoietic malignancies characterized by abnormal ampli- fication of one or more myeloid lineages ...
8
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
... Classical myeloproliferative neoplasms (MPN) according to the WHO classification constitute a group of hematopoietic malignancies and comprise chronic mye- loid leukemia (CML), polycythemia vera (PV), ...
7
Myeloproliferative neoplasms (MPNs) – Part 2: A nursing guide to managing the symptom burden of MPNs
... Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone marrow stem cells. The symptom burden experienced by patients with the ...
7
Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms
... We characterized bone marrow stromal cells (BMSC) from patients with pre-fibrotic myeloproliferative neoplasms (MPN). MPN-BMSC showed decreased capacity to stimulate the proliferation of colony-forming ...
5
Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
... Philadelphia-negative myeloproliferative neoplasms (MPNs) and respec- tive associations of anxiety and depression with demographic and lifestyle factors, comorbidity burden, duration of MPN disease, ...
11
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
... Herein, we report the identification and evaluation of ZT55, a natural product derived from Isatis indigotica Fort. (a popular, traditional Chinese medicinal herb), dis- covered by means of a high-throughput screening ...
12
Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
... Background: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix ...
14
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
... myeloproliferative neoplasms (MPNs). We performed high resolution melting analysis and Sanger sequencing together with T-A cloning to elucidate the unique mutation profile of these genes, in Chinese ...
10
Bone marrow aspiration and trephine biopsy in myeloproliferative neoplasms –An experience from a tertiary care centre
... Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal-origin hematopoietic stem cells alterations, characterized by excessive production of myeloid-lineage cells, which is reflected in ...
6
Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms
... W515L-induced myeloproliferative neoplasms (MPNs) by substituting either or both of them with phenylalanine in MPL W515L (termed as MPL515/625, MPL515/630 and MPL515/625/630, ...
13
IL 33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
... Myeloproliferative neoplasms (MPNs) comprise a heterogeneous group of malignant clonal hematopoietic diseases including, among others, BCR-ABL1–negative polycythemia vera (PV), essen- tial thrombocythemia ...
14